| Sep 26 |
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
|
| Sep 25 |
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
|
| Sep 9 |
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
| Sep 9 |
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
| Aug 12 |
Pacira downgraded by J.P. Morgan, Piper, RBC, Raymond James
|
| Aug 12 |
Where Pacira BioSciences Stands With Analysts
|
| Aug 9 |
Pacira Biosciences plummets 48% as judge rules Exparel patent invalid
|
| Aug 9 |
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
|
| Aug 7 |
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
| Aug 4 |
Pacira BioSciences, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
